Continuous infusional 5-fluorouracil in breast cancer or the revival of an old drug?

Annals of Oncology

Volumn 7, Issue 8, 1996, Pages 771-772

  Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

BREAST CANCER; EDITORIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029958739     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010754     Document Type: Editorial

References (13)

1. Heidelberger C. Chaudhuari N.K. Danenberg P. Fluorinated pyrimidines: A new class of tumour inhibitory compounds Nature 179 1957 663 666
2. Ensminger W.D. Rosowsky A. Raso V. A clinical pharmocologic evaluation of hepatic arterial infusion of 5-fluoro-2-deoxyruridine and 5-fluorouracil Cancer Res 38 1978 3784 3792
3. Sullivan R.D. Young C.W. Miller E. The clinical effects of the continuous administration of fluorinated pyrimidines (5-fluorouracil and 5-fluoro-5-deoxyuridine) Cancer Chemother Rep 8 1960 77 81
4. Lokich J. Bothe A. Fine N. Perri J. Phase I study of protracted venous infusion of 5-fluorouracil Cancer 48 1981 2565 2568
5. Lokich J.J. Ahlgren J.D. Gullo J. A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program Study J Clin Oncol 7 1989 425 432
6. Cameron D.A. Gabra H. Leonard R.C.F. Continuous 5-fluorouracil in the treatment of breast cancer Br J Cancer 70 1994 120 124
7. Huan S. Pazdur R. Singhakowinta A. Low-dose continuous infusion 5-fluorouracil: Evaluation in advanced breast cancer Cancer 63 1989 419 422
8. Regazzoni S. Pesce G. Marini G. Low-dose continuous intravenous infusion of 5-fluorouracil for metatastic breast cancer Ann Oncol 7 1996 807 813 (this issue)
9. Jones A.L. Smith I.E. O'Brien M.E.R. Phase II study of continuous infusion 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: An active new regimen J Clin Oncol 12 1994 1259 1265
10. Smith I.E. Walsh G. Jones A. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer J Clin Oncol 13 2 1995 424 429
11. Spicer D.V. Ardalan B. Daniels J.R. Re-evaluation of the maximum tolerated dose of continuous infusion of 5-fluorouracil with pharmacokinetics Cancer Res 48 1988 459 461
12. Heggie G.D. Sommadossi J.-P. Cross D.S. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile Cancer Res 47 1987 2203 2206
13. Porter D.J.T. Chestnut W.G. Merrill B.M. Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil J Biol Chem 267 1992 5236 5242